Form 4: BioAffinity Technologies Director Gary Rubin Acquires Shares
SEC Form 4
Gary Rubin, a director and 10% owner of bioAffinity Technologies, acquired 8,296 shares of common stock on June 12, 2024.
Summary
- On June 12, 2024, Gary Rubin, a director and 10% owner of bioAffinity Technologies, acquired 8,296 shares of common stock.
- The shares were granted as restricted stock and vested immediately.
- Rubin directly owns 112,813 shares and indirectly owns 1,584,144 shares through the Harvey Sandler Revocable Trust, where he serves as co-trustee.
- Rubin disclaims beneficial ownership of the shares held by the trust except to the extent of his pecuniary interest.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction of share acquisition by a director, which could be interpreted as a positive sign, but without further context, it's difficult to gauge the overall impact.
Positives
- The acquisition of shares by a director and 10% owner could be seen as a positive signal about the company's prospects.
Stakeholder Impact
- The share acquisition could have a minor positive impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of transaction: Gary Rubin acquired 8,296 shares of common stock. |
| 06/14/2024 | Date of signature for the Form 4 filing. |
Keywords
bioAffinity Technologies, BIAF, Gary Rubin, share acquisition, Form 4, beneficial ownership, Harvey Sandler Revocable Trust, director, 10% owner
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.